[1] William WN, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011;8:611–9. https://doi.org/10.1038/nrclinonc.2011.90.
[2] Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 2017;14. https://doi.org/10.1038/nrclinonc.2017.71.
[3] Siebel C, Lendahl U. Notch Signaling in Development, Tissue Homeostasis, and Disease. Physiol Rev 2017;97:1235–94. https://doi.org/10.1152/physrev.00005.2017.
[4] Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, et al. Noninvasive interrogation of DLL3 expression in metastatic small cell lung cancer. vol. 77. 2017. https://doi.org/10.1158/0008-5472.CAN-17-0299.
[5] Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3- targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor- initiating cells in vivo. Sci Transl Med 2015;7:302ra136-302ra136. https://doi.org/10.1126/scitranslmed.aac9459.
[6] Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell- selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011;17:1685–91. https://doi.org/10.1038/nm.2554.
[7] Sato K, Choyke PL, Hisataka K. Selective cell elimination from mixed 3D culture using a near infrared photoimmunotherapy technique. J Vis Exp 2016;2016:8–11. https://doi.org/10.3791/53633.
[8] Sato K, Nagaya T, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: Preclinical experience. Theranostics 2015;5:698–709. https://doi.org/10.7150/thno.11559.
[9] Sato K, Hanaoka H, Watanabe R, Nakajima T, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer. Mol Cancer Ther 2014. https://doi.org/10.1158/1535-7163.MCT-14-0658.
[10] Sato K, Choyke PL, Kobayashi H. Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model. PLoS One 2014;9. https://doi.org/10.1371/journal.pone.0113276.
[11] Sato K, Nagaya T, Mitsunaga M, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy for lung metastases. Cancer Lett 2015;365:112–21. https://doi.org/10.1016/j.canlet.2015.05.018.
[12] Sato K, Nagaya T, Nakamura Y, Harada T, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model. Oncotarget 2015;6:19747–58. https://doi.org/10.18632/oncotarget.3850.
[13] Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017;18:42–51. https://doi.org/10.1016/S1470-2045(16)30565-4.
[14] Ramirez RD, Kurie J, Michael DiMaio J, Vaughan MB, Milchgrub S, Smith A, et al. O-205 Immortalization of normal human bronchial epithelial cells (NHBEC) in the absence of viral oncoproteins. Lung Cancer 2004;41:S60–1. https://doi.org/10.1016/s0169-5002(03)91863-0.
[15] Adachi T, Nonomura S, Horiba M, Hirayama T, Kamiya T, Nagasawa H, et al. Iron stimulates plasma-activated medium-induced A549 cell injury. Sci Rep 2016;6:20928. https://doi.org/10.1038/srep20928.
[16] Hong W -S, Saijo N, Sasaki Y, Minato K, Nakano H, Nakagawa K, et al. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer 1988;41:462–7. https://doi.org/10.1002/ijc.2910410325.
[17] Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 1990;26:313–7. https://doi.org/10.1007/BF02897284.
[18] Kiura K, Watarai S, Ueoka H, Tabata M, Gemba KI, Aoe K, et al. An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line. Anticancer Res 1998;18:2957–60.
[19] Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I. Acta Medica Okayama Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 1992;46.
[20] Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, et al. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. Anticancer Res 2004;24:3911–6.
[21] Sato K, Watanabe R, Hanaoka H, Harada T, Nakajima T, Kim I, et al. Photoimmunotherapy: Comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Mol Oncol 2014;8:620–32. https://doi.org/10.1016/j.molonc.2014.01.006.
[22] Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3- targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor- initiating cells in vivo. Sci Transl Med 2015;7:302ra136-302ra136. https://doi.org/10.1126/scitranslmed.aac9459.
[23] Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, et al. Prevalence of Delta- like protein 3 expression in patients with small cell lung cancer. Lung Cancer 2018;115:116–20. https://doi.org/10.1016/j.lungcan.2017.11.018.
[24] Sato K, Nakajima T, Choyke PL, Kobayashi H. Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. RSC Adv 2015;5:25105–14. https://doi.org/10.1039/C4RA13835J.
[25] Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med 2019;11. https://doi.org/10.1126/scitranslmed.aav0891.
[26] Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL, Srkalovic G, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive- stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol 2019;37:222–9. https://doi.org/10.1200/JCO.18.00264.
[27] Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798–811. https://doi.org/10.1158/2159-8290.CD-12-0112.
[28] Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, et al. PAXIP1 potentiates the combination of WEE1 inhibitor AZD1775 and platinum agents in lung cancer. Mol Cancer Ther 2016;15:1669–81. https://doi.org/10.1158/1535-7163.MCT-15-0182.
[29] Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J, et al. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer. Clin Cancer Res 2017;23:6239–54. https://doi.org/10.1158/1078-0432.CCR-17-1284.
[30] Makita S, Tobinai K. Targeting EZH2 with tazemetostat. Lancet Oncol 2018;19:586–7. https://doi.org/10.1016/S1470-2045(18)30149-9.
[31] Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med 2016;22:128–34. https://doi.org/10.1038/nm.4036.
[32] Schulze AB, Evers G, Kerkhoff A, Mohr M, Schliemann C, Berdel WE, et al. Future options of molecular-targeted therapy in small cell lung cancer. Cancers (Basel) 2019;11. https://doi.org/10.3390/cancers11050690.
[33] Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 2007;7:327–31. https://doi.org/10.1038/nrc2130.
[34] Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, et al. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Cancer Sci 2019:1599–608. https://doi.org/10.1111/cas.13997.
[35] Deng SM, Yan XC, Liang L, Wang L, Liu Y, Duan JL, et al. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice. Biochem Biophys Res Commun 2017;483:488–94. https://doi.org/10.1016/j.bbrc.2016.12.117.
[36] Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, et al. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Clin Cancer Res 2019:1–10. https://doi.org/10.1158/1078-0432.ccr-19-1133.
[37] Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res 2019:acs.accounts.9b00273. https://doi.org/10.1021/acs.accounts.9b00273.
[38] Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, et al. Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy. ACS Cent Sci 2018:acscentsci.8b00565. https://doi.org/10.1021/acscentsci.8b00565.
[39] Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res 2018;7:69–79. https://doi.org/10.21037/tlcr.2018.01.16.
[40] Sato K, Nagaya T, Mitsunaga M, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy for lung metastases. Cancer Lett 2015;365:112–21. https://doi.org/10.1016/j.canlet.2015.05.018.
[41] Ito K, Mitsunaga M, Nishimura T, Saruta M, Iwamoto T, Kobayashi H, et al. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer. Bioconjug Chem 2017;28:1458–69. https://doi.org/10.1021/acs.bioconjchem.7b00144.
[42] Ito K, Mitsunaga M, Arihiro S, Saruta M, Matsuoka M, Kobayashi H, et al. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. BMC Cancer 2016;16:1–10. https://doi.org/10.1186/s12885-016-2072-0.
[43] Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Hodge JW, et al. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget 2016;8:8807–17. https://doi.org/10.18632/oncotarget.12410.
[44] Sato K, Sato N, Xu B, Nakamura Y, Nagaya T, Choyke PL, et al. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci Transl Med 2016;8. https://doi.org/10.1126/scitranslmed.aaf6843.
[45] Sato K, Watanabe R, Hanaoka H, Nakajima T, Choyke PL, Kobayashi H. Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. Oncotarget 2016;7:14324–35. https://doi.org/10.18632/oncotarget.7365.
[46] Okuyama S, Nagaya T, Sato K, Ogata F, Maruoka Y, Choyke PL, et al. Interstitial near-infrared photoimmunotherapy: effective treatment areas and light doses needed for use with fiber optic diffusers. Oncotarget 2018;9:11159–69. https://doi.org/10.18632/oncotarget.24329.
[47] Nagaya T, Okuyama S, Ogata F, Maruoka Y, Choyke PL, Kobayashi H. Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer. Cancer Sci 2018;109:1902–8. https://doi.org/10.1111/cas.13621.
[48] Nakajima K, Kimura T, Takakura H, Yoshikawa Y, Kameda A, Shindo T, et al. Implantable wireless powered light emitting diode (LED) for near-infrared photoimmunotherapy: device development and experimental assessment in vitroand in vivo. Oncotarget 2018;9:20048–57. https://doi.org/10.18632/oncotarget.25068.